M&A / Deals Beren pockets $300m to take Niemann-Pick disease therapy to market Pharmaceutical TechnologyIf approved, Beren's adrabetadex would join Zevra Therapeutics' Miplyffa and IntraBio's Aqneursa on the I-NPC market.Rare DiseaseRead full story pharminent June 11, 2026 (Last updated: June 15, 2026) Pharmaceutical Technology If approved, Beren’s adrabetadex would join Zevra Therapeutics’ Miplyffa and IntraBio’s Aqneursa on the I-NPC market. Rare Disease Read full story Post navigation Previous: Aquipta recommended by NICE for acute migraine treatmentNext: Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
